The risk of occurrence CDI for hospitalized patients using PPIs for SUP was higher than using H2RAs. It is recommended not to exceed 14 days of any gastric ASDs for SUP during hospitalization, especially for patients who have used high-risk antibiotics, been admitted to the ICU, or have immunodefici …

The online version contains supplementary material available at 10.1007/s13205-024-04102-7.

YARDLEY, PA — Groundbreaking research published in the Journal of Occupational and Environmental Hygiene reveals a 99.98% reduction in harmful toilet plume aerosols (TPAs) using the Splashblocker toilet cover. This innovative …

Q: I was sick for months with debilitating pain, extreme weight loss, fatigue and loss of appetite. I was diagnosed with C. diff related to an abdominal surgery. I'm being

The human intestine hosts a complex ecosystem of various microorganisms, collectively known as the gut microbiome, which significantly impacts human health. Disruptions in the gut microbiome are linked to various disorders, including gastrointestinal diseases, such as Clostridioides difficile …

Clostridioides difficile infection (CDI) represents a significant challenge due to its increasing incidence, severity, and treatment difficulty. Effective management requires a multifactorial approach that includes preventive strategies, prudent antibiotic use, and adapted therapeutic options. Ongoi …

Recurrent C. difficile infection (rCDI) is an urgent public health threat, for which the last resort and lifesaving treatment is a fecal microbiota transplant (FMT). However, the exact mechanisms that mediate a successful FMT are not well-understood. Here, we use longitudinal stool samples co …

Background: The impact of ultraviolet-C (UV-C) emitter configuration on pathogen attenuation has not been assessed. We hypothesized that emitter configuration would impact UV-C efficacy for Clos...

Clostridium difficile (C. difficile) is one of the most threatening bacteria globally, causing high mortality and morbidity in humans and animals, and is considered a public health threat that requires urgent and aggressive action. Interruption of the human gut microbiome and the development of anti

Clostridioides difficile infection (CDI) is an urgent public health threat with limited preventative options. In this work, we developed a messenger RNA (mRNA)-lipid nanoparticle (LNP) vaccine targeting C. difficile toxins and virulence factors. This multivalent vaccine elicited robust …

This study highlights fidaxomicin’s advantages over vancomycin, including lower recurrence rates of CDI and higher sustained clinical responses.

CDI is the leading cause of nosocomial post-operative care, with limited clinical cases and poor patient prognosis, and comprehensive clinical treatment guidelines are still lacking. This infection can be triggered by a variety of factors, including intestinal hypoxia, inappropriate antibiotic use, …

Scientific Reports - Safety and efficacy assessment of fecal microbiota transplantation as an adjunctive treatment for IgA nephropathy: an exploratory clinical trial

Since the 2021 guideline update, fidaxomicin use has increased significantly but could be further utilized given its association with better clinical outcomes and no increase in postdischarge costs.

Clostridioides difficile infection is the most common cause of antibiotic-associated diarrhea. IDSA/SHEA, ESCMID and ACG updated the clinical practice guidelines for CDI in 2021. This paper is an attempt to summarize these guidelines. The clinical presentation of Clostridioides difficile...

By Tiffany Whitfield and Isaiah Hudson   Curiosity is the engine that drives research amongst faculty in the College of Sciences, and uncovering new ways to fight one of the world’s most antibiotic-resistant pathogens is what drives Associate Professor Erin Purcell. At Old Dominion University, Purcell's area of research focuses on signal transduction pathways in Clostridoides difficile (C. difficile) which is a human pathogen that causes damage to the colon and can be fatal.

Our sheets and pillows are where we spend a third of our daily lives, and all that contact creates the perfect environment for all sorts of unwanted guests.

Nature Communications - Xinchen Lv and colleagues design pan-specific protein mini-binders that neutralize Clostridioides difficile toxin B (TcdB) and solve TcdB-binder complex structures via...

The German molecular diagnostics and reagents firm said it has converted more than 80 percent of a planned total of 180 products to the new IVDR regulatory framework.

GoodBiome™ Foods are functional foods containing a probiotic (Bacillus subtilis HU58™) and prebiotics (mainly inulin). Their effects on the human gut microbiota were assessed using ex vivo SIFR® technology, which has been validated to provide clinically predictive insights. GoodBio …

Clostridioides difficile may constitute a small part of normal gut microbiota in humans without causing any symptoms, but an uncontrolled growth common to hospitalized patients can cause Clostridioides difficile infection (CDI) leading to severe colonic symptoms. As the bacteria are attaining resist …

Antimicrobial resistance poses a major threat to global health and food security and is primarily driven by antimicrobial use in human and veterinary medicine. Understanding its epidemiology at farm level is crucial for effective control measures. Despite the significant reduction in antibiotic use …

Toxins TcdA and TcdB are the main virulence factors of Clostridioides difficile, a leading cause of hospital-acquired diarrhea. Despite their importance, there is a significant knowledge gap of druggable targets for inhibiting toxin production. To address this, we screened non-antibiotic phytochemic …

HA-CDI is associated with a higher risk of anastomotic leak after oncological colorectal surgery, while asymptomatic CDC do not have higher morbidity and may be operated electively, under standard CD treatment.

Global Clostridium Diagnostics Market is valued at approximately USD 838.05 million in 2022 and is anticipated to grow with a healthy growth rate of more than 7.10% over the forecast period 2023-2030.

C. diff survivor and Peggy Lillis Foundation Board Member Maryann Webb discusses how her experience with the infection encouraged her to advocate for patients who are struggling to advocate for themselves.

The Business Research Company recently released a comprehensive report on the Global Difficile Associated Diarrhea Treatment Market Size and Trends Analysis with Forecast 2024 2033 This latest market research report offers a wealth of valuable insights and data including global ...

Acurx reports ibezapolstat's positive microbiome effects and Anthrax activity

• One hundred seven patients with cystic fibrosis (CF) and 54 other patients with risk factors for Clostridium difficile–associated disease were entered into a bacteriologic study to compare the rate of recovery of C difficile and cytotoxin in feces with occurrence of diarrhea and to investigate...

Clostridioides difficile, a gram-positive, toxin-producing, spore-forming anaerobe, is a major cause of antibiotic-associated diarrhoea. The bacterium's intrinsic drug resistance limits current treatment options to fidaxomicin and vancomycin for initial episodes, with anti-toxin B monoclonal antibod …